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INTRODUCTION
Lung cancer is one of the most common solid tumors in many countries of the world, including United States and Japan, representing the primary cause of mortality among deaths from cancer. Although 30-40% of the patients with lung cancer can have a benefit of radiotherapy, but approximately 20% of them develop radiation-induced pulmonary injury.
Acute and subacute radiation pneumonitis, with late occurrence of fibrosis, are well known risk factors for Quality of Life (QOL) and survival of patients receiving radiotherapy to the thoracic field. However, there has been no previous report on effective treatment or prophylaxis.
According to clinical researches investigating the circulating cytokines in relation to radiation-induced pulmonary injury, the levels of IL-6 and transforming growth factor (TGF)-may serve as a predictor for the occurrence of radiation pneumonitis (1) (2) (3) . We previously reported that irradiation stimulated IL-6 production and accelerated transcription of its receptors, and increased cell proliferation via predictable IL-6/IL-6R autocrine/paracrine system in human lung fibroblastic cell lines (4) . All-trans-retinoic acid (ATRA), a physiological metabolite of Vitamin A, is known to affect cell differentiation, proliferation and development, and has been widely used for differentiating therapy of acute promyelocytic leukemia (APL) with the ability to overcome PML/RAR fusion protein. There have been several reports about the effects of ATRA on cytokine production (5) (6) (7) (8) (9) (10) . ATRA induced the 4 growth inhibition of myeloma cells, which proliferated in IL-6 autocrine and paracrine mechanism, with the reduction of both IL-6 production and its receptor expression (11) (12) (13) . In the previous report, we demonstrated that ATRA reduced irradiation-induced production of both IL-6 and its receptors in the lung fibroblasts, IL-6-dependent cell growth, and also directly inhibited the proliferation of lung fibroblasts after irradiation as well as anti-human
IL-6R antibodies (4).
Pulmonary fibrosis is frequently associated with collagen diseases, rheumatoid arthritis, and drugs including anticancer agents. Idiopathic pulmonary fibrosis (IPF) is the most common type with a prevalence of 16-18 per 100,000 persons, characterized by progressive worsening in pulmonary function leading to high incidence of death (>50% 5-year mortality rate) due to ultimate respiratory failure (14) . There have been a number of reports on cytokines being associated with lung fibrosis in animal models, including IL-6, TGF-1 , and PDGF by overexpression of cytokine genes (15) . Currently, however, there has been little progress in effective therapeutic and preventive strategies (16) (17) (18) .
Here we report the suggested inhibitory effect of ATRA on fibrotic changes both in irradiatedand in bleomycin-treated mouse lung tissues, resulting in the reduction of lethal effect caused by irradiation.
5

Methods
Cell culture
All cells; IMR-90, a cell derived from human fetal lung fibroblasts, Beas2B, a human bronchial epithelial cell line, HPAEC, a normal human pulmonary artery endothelial cell, and LEC, a normal human lymphatic endothelial cell, were cultured and irradiated with 8 Gy rays as previously described (4) . ATRA (Sigma) was added to the growth medium to yield the final DMSO solvent concentration < 0.2 % (v/v). In some experiments, the cells were preincubated either with NF-B inhibitor MG-132 (5 µM, Calbiochem, San Diego, CA) (19), JNK inhibitor SP600125 (10 µM, Calbiochem) (20) , p38MAPK inhibitor SB203580 (10 µM, Calbiochem) (21), or ERK1/2 inhibitor PD98059 (25 µM, Calbiochem) (19) for 60 minutes prior to irradiation.
The concentrations of IL-6, TGF-1 , TNF-and IL-ዊ were measured by ELISA Kit (BioSource, Camarillo, CA) in the culture supernatants with or without ATRA (10 -6 M) for 24
hours.
Animal studies C57BL/6 female mice were purchased from Japan SLC (Shizuoka, Japan) and maintained in our specific pathogen-free animal facility. All animals were kept according to the Animal 
Quantitative real time RT-PCR
RNA preparation and quantitative real-time RT-PCR was performed as previously described (4), using TaqMan Gene expression products for human TGF-1 , mouse IL-6, TGF-1 and COL1A1. 18SrRNA served as an endogenous control (Applied Biosystems).
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Collagen protein measurement IMR90 cells were 8Gy irradiated and cultured in the presence or absence of ATRA, and after 7day-culture, cells were collected and examined for the amount of collagen using Sircol soluble collagen assay Kit (Biocolor, Belfast, N. Ireland).
Immunofluorescence staining
Immunofluorescence staining was performed as previously described (4) . The fixed cells were stained with mouse anti-human SMA monoclonal antibody (1:100) (Sigma) followed by rhodamin-conjugated donkey anti-mouse antibody (1:1000) (Jackson Immuno Research Laboratories Inc, West Grove, PA). Hoechst33258 fluorochrome (Sigma) was used for nuclear staining. The exposure time of fluorescence microscopy was fixed to 1.5 seconds.
Measurement of NF-B p65 and p38MAP kinase
After treatment, nuclear extracts and cytoplasmic extracts were prepared by Nuclear Extract Kit (Active Motif, Carlbad, CA), and nuclear NF-B p65 and cytoplasmic phospho-p38MAPK (pThr 180 /pThr 182 ) were detected by ELISA Kit (BioSource and Sigma, respectively).
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Statistical analysis
Results are given as the mean ± SD of values. Statistical analysis was performed using Bonferroni/Dunn multiple comparisons test. Estimate of the probability of survival was calculated by the Kaplan-Meier method and compared using the log-rank test.
RESULTS
Effect of systemic administration of ATRA on survival rate in irradiated mice
Eight-week-old mice were 20 Gy irradiated selectively to the thoracic field, with (n=10) or without (n=11) ATRA (0.5 mg/body) intraperitoneally administered 3 times per week during the time course. After irradiation, the survival rate at 20 days in mice that received ATRA was 73.3%, and 76.9% in mice without ATRA. The main causes of death in the early phase were probably acute lung injury or bone marrow failure, which was not related to the addition of ATRA. However, the mice without ATRA started to die after the 12th week, leading to the survival rate at 16th week of 30%, while this was 81.8% in ATRA treated mice (p=0.0412, Fig.   1 ).
The histological changes in irradiated mouse lung with or without ATRA 9 The histological changes at 16 weeks are shown in Fig.2A . In the lung tissues from the irradiated mice without ATRA, pulmonary interalveolar septa became thickened and infiltrated by inflammatory cells, with collagen depositions in the interstitium disclosed by Azan staining, which were far less remarkable in those treated with ATRA. Mice treated by ATRA without irradiation showed no changes at all (data not shown).
The levels of mRNA of IL-6, TGF-1 and COL1A1 in mouse lung tissues
We previously reported that irradiation increased IL-6 production from cultured lung fibroblasts and lung tissues of mice, and that this could be reduced by the addition of ATRA (4) . In this report, mRNA levels of IL-6 from lung tissues of mice 16 weeks after 20 Gy irradiation were analyzed and shown to be approximately 15-fold elevated by real time RT-PCR compared to control mice, which was significantly suppressed by the administration of ATRA (p<0.0001) (Fig.2B ).
TGF-1 is a well-known key cytokine in the process of human pulmonary fibrogenesis (22) . We examined the effect of irradiation and ATRA on TGF-production in mouse lung tissues. The mRNA levels of TGF-( Fig. 2C ) and collagen type I 1 (COL1A1) (Fig. 2D ), which reflects collagen synthesis, in the lung tissues of irradiated mice were highly elevated (approximately 6-and 2-fold, respectively) compared to control mice without irradiation and ATRA. Notably, in irradiated mice treated with ATRA, the levels were 10 markedly decreased (p<0.0001 and p=0.0001, respectively). Lung tissues from mice treated with ATRA without irradiation showed no changes in IL-6, TGF-1 , and COL1A1 mRNA levels in comparison with control mice (data not shown).
Effect of ATRA on TGF-1 production from human lung fibroblasts
In vitro, we previously reported the inhibitory effect of ATRA on IL-6 production and proliferation of lung fibroblasts after irradiation. Thus, we performed experiments to examine the effect of ATRA on TGF-production of lung fibroblasts. (Fig. 5B, C) .
Involvement of NF-B and p38MAPK in irradiation-induced TGF-1 production
To study the underlying mechanism of irradiation-induced stimulation of TGF-1 production, we asked whether any kinases are required for this process. The pretreatment with inhibitors for NF-B or p38MAPK led to a decrease both in the concentrations of TGF-1 in the culture supernatant and in TGF-1 mRNA levels back to the control level (Fig.6A, B) , whereas neither of the inhibitors for JNK or ERK1/2 affected the irradiation-induced TGF-1 production (data not shown). The level of nuclear NF-B p65 was increased 1.4-fold by irradiation, which was suppressed by p38MAPK inhibitor as well as ATRA (p=0.0022 and p=0.0025, Fig.6C ). The irradiation increased the level of phospho-p38MAPK (6.4-fold),
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which was decreased by ATRA (p< 0.0001). The addition of NF-B inhibitor, on the other hand, had no effect on irradiation-induced increase of phospho-p38MAPK (Fig.6D) .
SB203580 inhibited the irradiation-induced p38MAPK activation (data not shown).
Prevention of bleomycin-induced lung fibrosis by ATRA
We next examined the effect of ATRA on bleomycin-induced lung fibrosis in mice as previously reported by Khalil et al (24) . As shown in Fig.7A , intraperitoneal administration of ATRA three times per week inhibited the collagen deposition in the bleomycin-treated mouse lung tissues. Elevated mRNA levels of IL-6 (Fig.7B ), TGF- (Fig.7C) , and COL1A1
( Fig.7D ) (approximately 1.5-, 1.5-, and 3-fold, respectively) in bleomycin-treated mouse lung tissues decreased after the treatment with ATRA (p=0.0022, p=0.0002, and p<0.0001, respectively).
Both early and late preventive effects of ATRA on irradiation-and bleomycin-induced lung fibrosis
To study the "preventive" and "therapeutic" effects of ATRA on lung fibrosis, we examined the same in that the three administration courses led to the significant suppression of fibrosis in the lung (Fig.8A ). In addition, mice were sacrificed at 28 days after injection intraperitoneally with bleomycin in the absence or presence of ATRA, and the level of fibrosis was measured as above. ATRA was administrated in three ways: (1) for the first 14 days (2) for the last 14 days, and (3) throughout the course, but again all administration courses resulted in the inhibition of lung fibrosis (Fig.8B) . Taken together, these results demonstrate the "late", namely "therapeutic" effect of ATRA in both irradiation-induced and bleomycin-induced lung fibrosis models, in addition to the "early", namely "preventive" effect.
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DISCUSSION
In this study, we showed preventive and therapeutic effects of ATRA on the progression of lung fibrosis both in irradiated and in bleomycin-treated mice. Increased IL-6 and TGF-1 mRNA levels in the lung tissues of both models were inhibited by ATRA. ATRA also inhibited irradiation-induced transdifferentiation process, in addition to the inhibitory effect on irradiation-induced cell proliferation as we previously reported (4). Taken together, ATRA appears to exert its effect through inhibition of both proliferation and differentiation of lung fibroblasts and prevents radiation-and bleomycin-induced pulmonary fibrosis in mice.
Several factors have been reported to be released from irradiated cells, including TGF-1 , tumor necrosis factor (TNF)-, IL-1 and IL-6, platelet-derived growth factor, vascular endothelial growth factor and fibroblast growth factor (25) (26) (27) (28) (29) (30) (31) . Among these cyotokines, the levels of IL-6 and TGF-1 appear to serve as a predictor for the occurrence of radiation pneumonitis (1-3). In fact, it has been shown that these levels in bronchoalveolar lavage fluid collected from irradiated areas increased progressively during lung irradiation, suggesting more direct local effects on the tissues (32) . In this study, the IL-6 mRNA levels in the irradiated mouse lung tissues were markedly increased as compared to control, and the level decreased by the addition of ATRA as shown in Fig.2B , which was compatible with our previous report (4). IL-6 stimulated proliferation of fibroblasts in a dose-dependent manner, and this effect was overcome by ATRA. On the other hand, it is well known that fibroblasts transdifferentiate to myofibroblasts, which express elevated levels of -SMA and consequently, display a markedly enhanced ability to contract extracellular matrix (33, 34) . In this study, the expression of -SMA was increased by irradiation in a dose dependent manner, with a maximum effect at 8Gy, which was the dose used throughout this study. As shown in In this study, we demonstrated that the inhibition of p38MAPK reduced irradiation-induced NF-B p65 activation, whereas the inhibition of NF-B had no effect on irradiation-induced p38MAPK activation (Fig. 6C, D) , which suggests that the activation of p38MAPK is necessary for NF-B activation. These results suggest a possible mechanism where ATRA could reduce irradiation-induced TGF-1 production through a p38MAPK and/or NF-B dependent pathway. These findings are summarized in Figure 9 . As we previously reported, irradiation induced IL-6 production and cell proliferation of lung fibroblasts. ATRA reduced irradiation-induced IL-6 production through PKC-/ NF-B pathway. In the present study, we showed that irradiation stimulated TGF-1 production and accelerated transdifferentiation of fibroblasts. ATRA inhibited irradiation-induced TGF-1 production through p38MAPK/ NF-B pathway, resulting in the inhibition of cell differentiation and collagen synthesis.
Pulmonary fibrosis is frequently associated with collagen diseases, rheumatoid arthritis, and with drugs including anticancer agents. We thus investigated another mouse model of lung fibrosis induced by bleomycin. We used bleomycin model not as an "IPF model", which might be limited in the late, post-inflammatory phase of repair following injury, but as a model for drug-induced lung fibrosis such as anti-cancer drugs. We treated mice with bleomycin by intraperitoneal administration instead of intratracheal administration as usually treated in many reports, because we wished to study the effect of the drug when added to the whole body since this administration better resembled the use of the drug in human cancer therapy. Pulmonary fibrosis is an inexorably progressive form of interstitial lung disease with various etiology including idiopathic pulmonary fibrosis (IPF). The median length of survival from the time of diagnosis of IPF varies between 2.5 and 3.5 years, and there has been remarkably little progress in the development of effective therapeutic strategies (14, (16) (17) (18) .
Here we report the preventive effect of ATRA on bleomycin-induced lung fibrosis in mice (Fig. 7A) . We also demonstrated that the treatment with bleomycin increased mRNA levels of both IL-6 and TGF-1 . Although the involvement of TGF-1 in bleomycin-induced lung fibrosis is well-known, we showed the effect of bleomycin on IL-6 production and the inhibitory effect of ATRA on the production of these causative cytokines. Additionally, ATRA inhibited bleomycin-induced COL1A1 mRNA expression which represents collagen synthesis.
The precise cellular mechanism has not been fully investigated, however, we propose a possibility that IL-6 and TGF-1 play an important role in this mouse model and ATRA prevents lung fibrosis through the inhibition of these cytokines similarly to irradiation-induced lung fibrosis.
It has been previously reported that a PDGFR/cAbl/cKit kinase inhibitor, imatinib mesylate was beneficial in the inhibition of lung fibrosis both by "anti-inflammatory" and "antifibrotic" mechanism in rat bleomycin model (46) . It is noteworthy that in this report we showed the "late" namely "therapeutic" effect of ATRA in both irradiation-induced and bleomycin-induced lung fibrosis models (Fig. 8 ) in addition to the "early", namely "preventive" effect, because in the clinical use the "therapeutic" effect is often more important when the clinicians find that the fibrotic changes are already apparent in their patients after irradiation or that they are suffering from fibrosis of various etiology.
ATRA is known to affect cell differentiation, proliferation and development. There have been some reports demonstrating that ATRA induced the growth inhibition of IL-6 dependent myeloma cells (11) (12) (13) and small cell lung cancer cells (47, 48) . Clinically, ATRA has been widely used in the differentiating therapy for acute promyelocytic leukemia (APL) (49) . Furthermore, the oral administration of the drug results in good compliance. Our data may lead to the development of novel strategies incorporating ATRA for the prevention and treatment of various types of lung fibrosis.
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Figure Legends 
